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As vascular surgeonsdthe corporal manifestation of cardiovascular specialistsdit follows that our duty to consider strategies to address this has never been more urgent. Although in its most basic form, vascular surgery is an intimate and local transaction between a surgeon and her patient, as medical and community leaders, I believe we also have the duty to look beyond each individual therapeutic relationship to the impact that the aggregate of our clinical decision-making has on our community and the world. The goal of this lecture will be to provide a bookmark in time reviewing the current state of aortic surgery around the world, to outline some of the more likely challenges we face in pursuit of equal provision of care for all and then some local strategies my team has humbly employed to initiate the first steps toward changing the status quo.
THE STATE OF THE AORTIC WORLD
Before addressing the vascular surgeon's social responsibility on the global burden of aneurysm disease, it was necessary to document the state of the profession with respect to five questions: who we are, how we train, where we work, what we do, and what it costs. I developed a measurement tool aimed to be administered over social networks to survey clinicians from around the world to determine the access to and use of endovascular aneurysm repair technologies in daily practice.
The self-administered survey was circulated on Twitter, Facebook, LinkedIn, and e-mail, both through my personal accounts and using an e-mail list provided without funding and compiled by BIBA medical. Any partially or fully trained clinician who repairs aneurysms as part of their daily practice would be encouraged to respond. Responses from individuals who complete the study but who identify as nonclinicians were excluded from final analysis. Attempts were made to decrease the risk of double counting respondents by including only the first response from each unique IP address. Consent for participation in the study was implied if a participant voluntarily completed the survey. A small disclaimer stating the same was placed on the first page of the study, in accordance with guidance from the local ethics committee. All participants were reassured that data would be analyzed and reported in aggregate only. For the purposes of this survey, Kazakhstan was considered to be in the continent of Asia, and the United Kingdom was considered to be in Europe.
The survey tool can be found in the Appendix (online only) and at the following link: https://www.survey monkey.net/r/Preview/?sm¼UXREDkc_2BQdRb8vVfHzrZ 0mBONnR_2BAcjgzeb8FxAzJO_2F0ukhGQLwnCb9OwZ lzbwo8SBYK_2B8IVaMLYshhZQYVGZUHbKqi9yt7uEblTx p97_2Bd8_3D.
After removing respondents who had no medical training, a total of 609 respondents remained, from 59 different countries. There were nine duplicated IP addresses, and the second entry from those was excluded. When asked to describe their current practice, 72% of respondents identified as vascular and endovascular surgery and only 8% of other respondents as vascular surgery with no endovascular surgery or vascular surgery with general surgery. This could represent the bias in the sample or an important change in the field. There were 34% of respondents who have been in practice for 10 to 20 years, 21% in practice 20 to 30 years, and 26% in practice 1 to 10 years. The distribution of older generation to younger generation in this study was consistent across geographic regions.
The charts in Figs 1 through 10 reveal the most pertinent findings of the survey. If the respondents' reports reflect the truth, aortic surgery has changed considerably in most jurisdictions since the introduction of endovascular repair to aneurysm disease and is now an endovascularbased practice: the training and practice of many vascular surgeons treating aneurysms has evolved to include endovascular skills, and >50% of aneurysms repaired worldwide are completed with endovascular techniques. However, the proportion of trained endovascular surgeons, the cost of endovascular devices, and the incorporation of stent grafts into aneurysm repair vary on the basis of geographic location. In keeping with early and later adopters of endovascular technology, half of the imaging equipment in the institutions of respondents was reported to be >10 years old, suggesting that repeated large capital investments will be required in the near future in many hospitals to maintain this level of minimally invasive therapy into the future. The most diverse training pool seems in be in Europe, where surgeons from all over the world converge for training. Reported device costs vary widely around the world, suggesting either a fundamental lack of understanding of surgeons using the devices or a serious inequality for patients in jurisdictions with the highest device costs.
CHALLENGES TO ADVANCING THE HIGHEST QUALITY AORTIC CARE AROUND THE WORLD
Having established the state of the global aortic community and the availability of both equipment and resources for aneurysm repair, the next task is to identify the challenges to equalizing these resources and ensuring that all patients have access to the proven "gold standard." Although many different variables could be cited as reasons for the slow diffusion of technology, there are four main causes that seem most pertinent in today's economic environment: the mismatch in access to care for those who are most likely to need cardiovascular treatment, the intrinsic bias that has developed in the funding for health care and research, the slow pace of evidence compared with the fast pace of innovation, and the models of surgical training that have not kept pace with the advancement of new technology.
Access mismatch. In many jurisdictions, despite the advancement of society and the increasing democratization of previously impoverished nations, there fails to be an acceptance of health care as a fundamental and basic human right. Lack of access to universal care is most obvious in large parts of Africa and Asia but can be found in pockets of all continents except Australia. 1, 2 In addition to lack of adequate universal care, the facilities available for patients who need treatment even if they could afford it are poor, with many areas of Africa and Asia having fewer than 10 hospital beds/10,000 population 3 compared with an average of 30 or more in North America and Europe. This becomes a more urgent problem when the statistics for most prevalent cause of death in the last 3 years are analyzed. With the dedication to vaccination and control of infectious disease being the main thrust of relief efforts in third-world nations, cardiovascular diseases and lifestyle-related lung diseases, such as chronic obstructive pulmonary disease, have become the predominant cause of death in even the most impoverished nations. These disease burdensdwhich require infrastructure for prevention programs and access to advanced, lifelong doses of expensive pharmaceuticals and high-cost, often technologically advanced treatments for managementddo not lend themselves to field hospital treatment in the paradigms we currently have available. This is further complicated by the fact that the heaviest burden of cardiovascular disease often occurs in patients with the highest level of deprivation or the lowest socioeconomic status. 4 Evidence generated from American sources suggests that lower socioeconomic status has become a statistically significant risk factor for early mortality, carrying a hazard ratio of 1.42 in men and 1.34 in women, which is higher than that of either obesity or hypertension in the same population. 5 This is particularly important in the treatment of aneurysm disease when the figures from National Health Service England's screening program are analyzed, showing that the incidence of aneurysms is greater in patients at higher levels of deprivation, and yet the proportion of patients in those same groups who access careddespite its universal availabilitydis disproportionately lower than in more privileged sections of English society. 6 In essence, the people with the least access or proclivity to seek care are the ones who need it most and are not benefiting, even when it is available. As vascular surgeons, I believe it is imperative that we recognize this paradox and move to change it. Funding bias. The next important challenge to the delivery of high-quality aortic surgery and treatment of aneurysm disease to every patient in the world is related to the funding for both health care systems and the research and development that drive them. The per capita spending for health care varies widely across jurisdictions and reflects access to care as mentioned before. 2 This also varies in an expected way with the life expectancies of the incumbent populations. Despite this, there is a documented phenomenon of misuse or overuse of health care services in all levels of health care systems, both those with limited funding and those with an abundance of resources. 7, 8 This is likely explained by very different factors at each level of resource: the desire to avoid litigation, a sense of entitlement, the lack of training in evidence-based care, the corruption of health care providers, or possibly the profit-driven motivations of others in a commercialized health care environment. The overuse of services can reach levels as high as 40% to 50%, as in the case of preoperative cardiac testing in patients undergoing noncardiac surgery as reported by a review of the literature by Brownlee et al. 9 Efforts to decrease the overuse or misuse of medical resources are being supported and encouraged by medical societies around the world. However, these "appropriate use"
campaigns rely on a diet of high-quality research to determine the most effective and efficient methods of diagnosis and treatment. What complicates this discussion is that the evidence generated to determine appropriate use, and in fact the evidence for treatment modalities of all sorts, is increasingly relying on medical industry funding rather than that from "purer" public and government funds. Commercial interests in the pharmaceutical and medical device industry have a twofold Volume of thoracoabdominal aortic aneurysm (TAAA) repairs performed using any modality, divided by the continent of respondent's current location of practice.
goal of both improving patient care and creating profit while increasing market share. Thus, even the most altruistic of our medical industry partners still has some motivation to generate evidence that supports the use of the product that they sell. In one analysis of medical research funding by Moses et al, 10 the proportion of medical research funded by industry increased from 46% to 59% between 1994 and 2012. As public institutions have a lesser influence on the types of research performed and the direction of medical investigation, the potential for influence on health care expenditure will drive the market. This bias is well documented as already existing in the medical literature; in a report of 169 randomized controlled trials published between 2008 and 2009, 40 of 69 trials (58%) contained data analyzed by the sponsor without the input of the academic authors, and in 93% (64/69 trials), the manuscript was either written or approved by the sponsor. 11 As long as health care industry continues to increase the research generated from nonpublic funds, the potential for health care expenditure to be biased by commercial interests remains strong. As the guardians of health care decisions, it is incumbent on vascular surgeons both to generate unbiased research and to make patient-centered treatment decisions that are free from industry bias.
Evidence lag. The increasing reliance on industry funding to drive research and innovation could be because the pace of innovation has outstripped the capacity for public funders to provide adequate resources. Innovation is more rapid now than in previous generations, and the reliance on technology in health care is becoming greater. The last few decades have provided a number of examples of clinical enthusiasm for new technology introduced into clinical use before the ramifications could be truly appreciated. The Bjork-Shiley valve, introduced in 1978, is one classic example. Although the construct and preclinical testing were sound, the valve developed postimplantation defects that had major clinical ramifications but were not noticed until significant numbers of valves were implanted. 12 In vascular surgery, early-generation endovascular devices could also fall into this category, as many developed late failure patterns after prolonged implantation that led to resumption of aneurysm growth but took years to be removed from the market. Unfortunately, these failing devices become a more cost-effective solution for resource-poor health care systems in the years before they are ultimately removed (Table) ; and some, as in the current case of the multilayer stent, which has been proven in a number of anecdotal and institutional reports to be less effective than traditional endografts at decreasing aneurysm sac size over time, [13] [14] [15] are still in circulation against the better judgment of many experts in the field. 16, 17 It would be impossible to delay the introduction of new technology until long-term studies were completed, as the pace of the introduction of these technologies with the ultimate discovery of need for improvement is one of the leading motivators for new iteration of technology. However, the opportunity loss in these situations is the failure for clinicians to meticulously document and collect data from every implantation, not just those performed under the auspices of an industry-sponsored trial. The need for real-time registries is great in this fast-paced innovative environment, and collaboration with large, clinically driven data sets may bring to light the patient safety issues before they have an impact on large segments of the population. Vascular surgeons need to be as keen to develop data technology to protect and care for our patients as we are to develop the devices and pharmaceuticals themselves.
Training models. The final challenge to the equitable distribution of technology to treat aneurysms lies in the training models in vascular surgery. Although many centers around the world have embraced high-technology solutions to the training of traditional surgeons in the very different endovascular modalities, these tend to be costly and not widely accessible. There exists a very different training paradigm for surgeons who are already in practice compared with those in training when new technology is introduced. The example of common bile duct injuries in patients undergoing laparoscopic cholecystectomy is illustrative. In a survey performed of 3656 surgeons across the United States who completed Accreditation Council for Graduate Medical Education residency, the incidence of common bile duct injury in those who learned the techniques while in training tended to occur later in practice, suggesting a period of more complex cases. However, those surgeons forced to retrain after already exiting formal training schemes were more likely to incur bile duct injuries very early in their experience, suggesting that they may have been learning in a more unsupported environment. 18 This phenomenon is doomed to recur every time there is an introduction of new technology into our clinical environments without supported educational systems, and it will have an impact on early outcomes. This "learning curve" phenomenon will bias early results, making more conservative health care systems less likely to adopt new technology, and make early maturing evidence more biased against the benefit of the technology itself. If the pace of innovation continues to accelerate, this may happen many times in a single surgical career, meaning that this learning curve effect will have an impact on mortality and morbidity of patients even in older and more experienced surgical hands. It is imperative that we focus on methods to diffuse the education for these new technologies as soon as they are available and create new models of education that are supportive and shorten the learning curve.
WHAT IS THE SOLUTION?
Analyzing the challenges to providing equitable access to the gold standard for aneurysm treatment across all geographic and socioeconomic jurisdictions creates a daunting challenge for our field and our time. There is no one solution that will address the multivariable causes that drive motivation for treatment on either the patient's or clinician's behalf. However, the development of data technology, the desire to collaborate and share the data collected, the development of learning models as innovative as the technology being taught, and the creative and innovative approach to conducting research that is independent of industry will be four major steps toward a solution. In our own approach at the Royal Free London, we believe that infusing our innovation with a spirit of altruism is the single most important element to ensure that we keep our compass pointed in the correct direction and maintain a more global focus. This "altruistic innovation" takes many forms and admittedly sometimes may not be successful. Some efforts are simple: we have developed web-based teaching videos for radiation dose awareness and critical care transport that we use as teaching tools in our own system but share freely with the world. Other efforts require the partnership of industry. We have worked with an advanced imaging company, Cydar Medical, to help test the use of fusion imaging on mobile C-arms so that fusion technology, which traditionally required the capital investment of a hybrid theater, can now be available in health care environments where hybrid theaters are not affordable. We are developing web-based applications for communications between referrers and team members in the setting of ruptured aneurysms that will coordinate care and, it is hoped, expedite the patient's timely access to operating theatersdand plan to share this technology after testing within the National Health Service and, if possible, with the larger vascular community. Finally, we have worked with European colleagues in France and Sweden to create and fund a registry for the collection of data in thoracoabdominal aneurysm repair without industry involvement, which we are sharing with European and Canadian colleagues to provide a platform for collaboration and data generation. 
